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Acute myeloid leukemia (AML) patients harboring the Fms-like tyrosine kinase 3 internal 
tandem duplication (FLT3-ITD) mutation are considered a particularly high risk patient subset 
preferentially allocated for allogeneic stem cell transplantation in first remission. Whether FLT3-
ITD retains a prognostic role in haploidentical stem cell transplantation (haplo-SCT) is currently 
unknown.   
Patients and methods 
Using the international multicenter registry of the acute leukemia working party of the European 
society for blood and marrow transplantation, we performed a retrospective analysis to determine 
whether FLT3-ITD was prognostically significant in T-cell replete haplo-SCT transplanted AML 
patients.  
Results 
We evaluated 293 de-novo AML patients (202 FLT3
wt
 and 91 FLT3-ITD
mut
) transplanted in first 
remission with T-cell replete haplo-SCT between 2005-2016. FLT3-ITD
mut
 patients were more 
likely to be NPM1 mutated as well as be in the intermediate risk cytogenetic risk category.  In 
multivariate analysis, patients with FLT3-ITD had comparable rates of relapse incidence [Hazard 
ratio (HR)=1.34, confidence interval (CI) 95%, 0.67–2.7; P=0.9]  and leukemia-free survival 
(HR=0.99, CI 95%, 0.62–1.57; P=0.9) to those of FLT3
wt
 patients. Survival was not significantly 
impacted by FLT3-ITD status (HR=0.96, CI 95%, 0.58–1.59; P=0.8), nor were the incidence of 
non-relapse mortality (HR=0.78, CI 95%, 0.41–1.46; P=0.44), and graft versus host disease-
free/relapse-free survival (HR=0.84, CI 95%, 0.54–1.28; P=0.42). Focused subset analysis of 
patients with intermediate risk cytogenetics confirmed the absence of a prognostic impact of 
FLT3-ITD also for this group of patients.   
Conclusion 
In AML patients undergoing T-cell replete haplo-SCT, the FLT3-ITD mutation does not retain its 
prognostic significance, potentially indicative of haplo-SCT’s capacity to overcome the negative 
prognostic consequences of FLT3-ITD in AML.   
 
Introduction 
Acute myeloid leukemia (AML) patients harboring the Fms-like tyrosine kinase 3 internal 
tandem duplication (FLT3-ITD) mutation are a particularly clinically challenging patient 
segment in the field of hematologic malignancies. Nearly a third of AML patients with baseline 
normal cytogenetics present with FLT3-ITD which has consistently been shown to confer poor 
long term outcomes resulting from a remarkably high relapse rate
1-8
. Whereas the negative 
prognostic impact imparted by FLT3-ITD is unequivocal, an ongoing debate in the field revolves 
around the question of whether allogeneic stem cell transplantation can overcome the detrimental 
impact of FLT3-ITD. In contrast to earlier published data
9
, and notwithstanding the paucity of 
randomized trials comparing transplantation with chemotherapy exclusive approaches, the bulk 
of current evidence suggests that allogeneic transplantation improves survival of FLT-ITD 
mutated patients
7,10-15
. Haploidentical stem cell transplantation (haplo-SCT) presents a valid 
option for those patients in need of allogeneic transplantation and lacking a fully matched HLA 
matched donor. The early experience with haplo-SCT was initially characterized by an increased 
incidence of transplant related mortality due to the slow kinetics of immune reconstitution 
leading to an increased incidence of fungal and viral infections as well as graft rejection
16
. 
However, significant advances in haplo-SCT have been recently realized with the introduction of 
novel immunosuppression modulation approaches, namely post-transplantation 
cyclophosphamide (PTCy)
17
 and anti-thymocyte globulin (ATG) based protocols
18
, which via 
selective in-vivo depletion of donor T cells have achieved acceptable rates of engraftment, thus 
negating the need for profound T cell depletion. Indeed, the evolving application of haplo-SCT 
in AML is evident with recent publications indicating comparable clinical outcomes between 
allogeneic transplantation from partially HLA mismatched (9/10) unrelated donors, and possibly 
HLA matched unrelated (10/10) donors and even HLA matched sibling donors to those of haplo-
SCT
19-24
, and therefore it is becoming imperative to characterize the impact of haplo-SCT on 
specific subsets of AML patients. As of yet, no formal evaluation of the impact of FLT3-ITD
 
on 
outcomes following haplo-SCT has been performed. In this analysis of 293 AML patients, we set 
out to determine whether FLT3-ITD maintained its prognostic significance for AML patients 






Study Design and Data Collection 
This analysis was a retrospective multicenter analysis performed by the Acute Leukemia 
Working Party (ALWP) of the European Society for Blood and Marrow Transplantation 
(EBMT). The latter is a voluntary working group comprising more than 500 transplant centers 
required to report on an annual basis on all transplants performed. Quality control measures of 
the multicenter registry include confirmation of the validity of the entered data by the reporting 
team, cross-checking with the national registries, and regular in-house and external data audits. 
Patients included in this analysis were adult de-novo AML patients, over the age of 18, 
undergoing a first T-cell replete related haplo-HCT from 2005 through 2016 while in first 
complete remission. This study was approved by the ALWP institutional review board and was 
conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. 
All patients provided written informed consent authorizing the use of their personal information 




Clinical outcomes were evaluated as follows: (I) non-relapse mortality (NRM), defined as death 
without previous relapse; (II) relapse incidence (RI), defined on the basis of morphological 
evidence of leukemia in bone marrow or other extramedullary organs; (III) leukemia-free 
survival (LFS), defined as the time from transplantation to first event (either relapse or death in 
complete remission); (IV) GVHD-free/relapse-free survival (GRFS), defined as events including 
grade 3-4 acute GVHD, extensive chronic GVHD, relapse, or death in the first post-HCT year
25
; 
and (V) overall survival. Cumulative incidence curves were used for RI and NRM in a 
competing risks setting, since death and relapse are competing. Probabilities of OS, LFS, and 
GRFS were calculated using the Kaplan–Meier estimate. The probabilities of NRM, RI, acute 
and chronic GVHD were calculated using the cumulative incidence estimator to accommodate 
for competing risks
26
. Univariate analyses were done using the Gray’s test for cumulative 
incidence functions and the log rank test for OS, GRFS, and LFS.  A Cox proportional hazards 
model was used for multivariate regression. Variables included in multivariate models were 
either with unbalanced distribution or potential impact on outcome. Results were expressed as 
the hazard ratio (HR) with the 95% confidence interval (95% CI). Proportional hazards 
assumptions were checked systematically for all proposed models using the Grambsch-Therneau 
residual-based test. All tests were 2-sided. The type 1 error rate was fixed at 0.05 for the 
determination of factors associated with time-to-event outcomes. Statistical analyses were 
performed with SPSS 22.0 (SPSS Inc, Chicago, IL, USA) and R 3.2.3 (R Development Core 




Patient, disease and transplant baseline characteristics  
The analyzed cohort comprised 293 patients transplanted between 2005-2016, 91 of whom were 
FLT3-ITD mutated. As summarized in table 1, compared to FLT3
wt
, the group of FLT3-ITD 
mutated patients did not differ to a significant degree with respect to patient age, donor age, 
performance status, and CMV donor-recipient matching. FLT3-ITD
mut
 patients were more likely 
to have ELN intermediate risk cytogenetics whereas poor risk cytogenetics were more frequently 
seen in FLT3
wt 
patients. Additionally, most of the FLT3-ITD
mut 
patients had a concomitant NPM1 
mutation while the majority of FLT3-ITD
wt 
patients did not have an NPM1 mutation (61% versus 
10%; P=0.0001). Conditioning intensity did not differ to a significant degree between FLT3-ITD 
mutated patients and FLT3
wt 
patients; supplementary table 1 outlines the various conditioning 
regimens used for patients in this analysis.  
Transplant outcomes 





patients with a 96% engraftment rate observed in both groups; P=0.9. At 2 years, the 
incidence of relapse was 17% (95% CI: 12.6-22) with a 61% (95% CI: 55.1-67.4) rate of 
leukemia-free survival. The overall survival rate was 66% (95% CI: 60.8-72.8) whereas non-
relapse mortality was seen in 21% of the patients on this cohort (95% CI: 16.9-27). Grade II-IV 
acute GHVD was experienced by 29% (95% CI: 24-34.6) of the patients while chronic GVHD 
was diagnosed in 36% (95% CI: 30.1-42.4) of patients. Extensive chronic GVHD was seen in 
11% of the patients (95% CI: 8.1-16.4). Supplementary table 2 outlines the main etiologies 
accounting for patient death in this analysis, with lethal infections and disease relapse being the 
leading causes for patient death.  
 
Impact of FLT3-ITD on clinical outcome  
To determine whether FLT3-ITD impacted on clinical outcome, we initially performed a 
univariate analysis which is summarized in table 2 and figure 1. Harboring FLT3-ITD did not 
significantly influence disease related clinical outcomes, namely relapse incidence (24% versus 
14%, P=0.1) and leukemia-free survival (55% versus 63%, P=0.49), nor did it affect in a 
statistically significant manner transplant related outcomes such as non-relapse mortality (20% 
versus 22%, P=0.62), acute and chronic graft versus host disease, and GVHD-free/relapse-free 
survival (49% versus 50%, P=0.79). Overall survival was also not impacted by the mutational 
status of FLT3-ITD (65% versus 67%, P=0.88). Notably, the presence or absence of a 
concomitant NPM1 mutation also did not influence clinical outcome in a statistically meaningful 
way. To assess whether the specific immunomodulation approach employed differentially 
affected outcome, a univariate analysis was carried out analyzing the outcomes of FLT3-ITD 
patients versus FLT3
wt
 in ATG and PTCy treated patients. As shown in supplementary table 3, 
both in PTCy and ATG treated patients, FLT3-ITD status did not influence outcome in a 
statistically significant way.  Finally, a multivariate analysis was carried out which as depicted in 
table 3, confirmed that FLT3-ITD mutational status did not significantly affect clinical and 
transplant related outcomes.  
 
Impact of FLT3-ITD on outcome of patients with intermediate risk cytogenetics 
Since most of the FLT3-ITD patients were in the ELN intermediate risk cytogenetics category, 
we repeated our analysis focusing specifically on the 210 patients with intermediate risk 
cytogenetics. In this subgroup analysis, whose baseline data are summarized in supplementary 4, 
patients not harboring the FLT3-ITD mutation were younger (39 versus 45; P=0.023), and were 
less likely to be given PTCy compared to their FLT3-ITD mutated counterparts (38% versus 
55%; P=0.004). For this group of patients the 2 year leukemia-free survival and overall survival 
rates were 59% and 66%, respectively, whereas relapse incidence and non-relapse mortality rates 
were 17% and 28%, respectively. Grade II-IV acute GVHD was observed in 28% of patients and 
chronic GVHD was diagnosed in 36%. As shown in figure 2, a univariate analysis followed by a 
multivariate analysis, summarized in table 4, confirmed that also for this group of patients, the 
presence of a FLT3-ITD mutation also did not influence disease or transplant related outcomes.  
 
Discussion 
Consequent to its high incidence and decidedly detrimental impact on patients, FLT3-ITD is 
considered the most important molecular determinant of outcome in AML patients. Thus, FLT3-
ITD patients are referred to transplant early during the therapeutic sequence with the hope that 
allogeneic stem cell transplantation will mitigate some of the unfavorable clinical magnitude 
associated with FLT3-ITD
27,28
.  In this analysis we attempted to determine whether in AML 
patients undergoing haplo-SCT, FLT3-ITD is still clinically meaningful following transplant. 
The results of our analysis show that outcomes of haplo transplanted AML patients were not 
significantly affected by FLT3-ITD
+
 status, thus challenging the notion that FLT3-ITD retains its 
negative impact even following allogeneic transplantation.  
The impact and justification for allogeneic SCT in FLT3-ITD AML has been extensively 
investigated in the last decade. It is now firmly accepted that FLT3-ITD patients treated with 
chemotherapy alone stand a very poor chance of long term survival resulting from reported 
relapse rates of over 70%
1-4,6,9,29
. Accordingly, the standard of care for these patients is 
transplantation in first remission
30,31
.  Whereas most publications in the field support a beneficial 




, we note a recently published 
CIBMTR analysis of 511 AML patients demonstrating that while FLT3 mutated patients had 
increased relapse incidence compared with patients without the mutation, the 3 year leukemia-
free survival and overall survival rates were not significantly different for both groups
33
. 
The emerging experience with haplo-SCT in AML is suggestive of a comparable degree of 
disease control with that of conventional stem cell sources, namely HLA matched sibling and 
unrelated donors
19-22
. Yet, to date the impact of FLT3-ITD in the setting of haplo-SCT has not 
been rigorously investigated. Our data indicate that the lack of a prognostic effect of FLT3-ITD, 
findings which diverge from the results of the recent analysis published by Wang and 
colleagues
22
, where FLT3-ITD was found to be associated with a decreased 3 year disease free 
survival rate compared with non FLT3-ITD mutated patients (60% versus 79%). However, as 
most patients in that analysis did not have FLT3-ITD testing performed, interpretation of these 
data are to some extent limited. Our clinical outcomes are generally in line with the 
abovementioned studies examining the role of haplo-SCT in AML, with the inherent limitation 
of different time points analyzed, thus further strengthening the generalizability of our findings. 
Why haplo-SCT would render FLT3-ITD a less precarious determinant of clinical outcome and 
harbinger of relapse in AML is not fully clear. A possible explanation to consider may stem from 
the markedly different immunological milieu encountered with the PTCy approach, namely the 
subsistence of quiescent progenitor cells and memory cells without the subset of alloreactive T-
cells
16
, which may consequently modulate the graft versus leukemia effect, possibly abrogating 
the detrimental effect of FLT3-ITD in terms of relapse incidence
34
. Moreover, it is conceivable 
that the limited use of immunosuppression after haplo-SCT, afforded by using PTCy which as 
noted earlier selectively depletes alloreactive T-cells while preserving anti leukemia T-cell 
subsets and NK cells, results in an increased graft versus leukemia effect
35
. Our data suggest that 
also for ATG treated patients, FLT3-ITD does not retain its prognostic significance which may 
be possibly accounted by an anti-leukemia effect of ATG as suggested by previously published 
registry data from China suggesting that in high risk acute leukemia patients, haplo-SCT with 
ATG prophylaxis resulted in lower leukemia relapse rates
36
. Further, recently published in-vitro 
data indicates that ATG may have intrinsic anti-leukemia activity
37
.   
Several important limitations to our analysis merit acknowledgement. As our knowledge of the 
molecular workings of AML expands, it is becoming clearly established that gene-gene 
interactions profoundly impact on the outcome of AML patients
38,39
, thus the presence of 
DNMT3A, IDH1, RUNX1, and additional modifying genes which were not captured in our 
registry may have contributed to our findings. The FLT3 allelic ratio is an additional prognostic 
component previously proposed to influence outcome of patients and which owing to the 
retrospective nature of dataset was not analyzed by us
32,40,41
. Finally, minimal residual disease 
(MRD) is increasingly being used to determine the depth of remission prior to stem cell 
transplantation and would decidedly further inform our analysis
42
.    
Taken together, the collective data in this analysis suggest that T cell replete haploidentical 
transplantation may conceivably mitigate the deleterious impact associated with FLT3-ITD in 
AML. Possible implications of our data are that T cell replete haplo-SCT may be a preferred 
therapeutic modality for this specific high risk subset of patients, a hypothesis that would need to 
be rigorously confirmed in randomized fashion.  
 
Figure legends: 
Figure 1. Clinical and transplant related outcomes of patients transplanted in first remission 
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Figure 2. Clinical and transplant related outcomes of intermediate risk patients transplanted in 
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